CJC-1295 w/ DAC 5mg

CJC-1295 DAC is an investigational synthetic peptide that functions as a GHRH analog. Its primary role in research is to stimulate endogenous growth hormone (GH) secretion. The key feature of CJC-1295 DAC is its prolonged half-life, which distinguishes it from other GHRH analogs, allowing for less frequent administration in research settings.

Researchers investigate CJC-1295 DAC for its potential to elicit sustained increases in growth hormone and insulin-like growth factor 1 (IGF-1) levels. This sustained elevation is thought to be beneficial in various research models where consistent growth hormone stimulation is desirable, without the peaks and troughs associated with shorter-acting GHRH secretagogues.

Mechanism of Action

CJC-1295 DAC works by binding to growth hormone-releasing hormone (GHRH) receptors in the anterior pituitary gland. This binding stimulates the pulsatile release of growth hormone (GH) from somatotroph cells. The 'DAC' (Drug Affinity Complex) portion of the peptide covalently binds to plasma albumin after administration, which protects it from enzymatic degradation and prolongs its circulation time and biological activity, leading to a sustained release of GH.

Structure and Class

CJC-1295 DAC is a 30-amino acid peptide hormone, often classified as a GHRH analog or a growth hormone-releasing factor (GRF) analog. Its specific modification with the Drug Affinity Complex differentiates it from unmodified GHRH or other GHRH-mimicking peptides, giving it an extended half-life. The 'DAC' refers to the maleimidoproprionic acid attached via a lysyl linker, which facilitates the binding to albumin.

Primary Research Areas

Primary research areas for CJC-1295 DAC include studies on its effects on growth hormone secretion dynamics, body composition changes, and metabolic processes in various research models. Investigators explore its potential in models related to muscle growth, fat loss, and recovery from injury due to its anabolic and regenerative properties mediated by increased GH and IGF-1.

Notable Peer-Reviewed Findings

Early research, including studies published in the Journal of Clinical Endocrinology & Metabolism, demonstrated that single injections of CJC-1295 DAC in investigational models led to dose-dependent and sustained increases in plasma GH and IGF-1 levels. These studies indicated that the DAC modification successfully prolonged the peptide's pharmacological action, reducing the frequency of administration needed to maintain elevated GH concentrations compared to unmodified GHRH. This sustained elevation of GH and IGF-1 was observed to last for several days to a week following a single dose.